Evidence map›Paper›PMID 41142752›Full record

ArticleComputational and structural biotechnology journal2025

Prioritizing cancer therapeutic genes using BioRank: A biologically-informed PageRank framework.

Duc-Tinh Pham, Huu-Tam Nguyen, Van-Hai Pham, Van-Thanh Le

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Duc-Tinh PhamSchool of Information and Communications Technology, Hanoi University of Industry, 298 Cau Dien street, Bac Tu Liem District, Hanoi, Viet nam.
Huu-Tam NguyenSchool of Information and Communications Technology, Hanoi University of Science and Technology, Hanoi, Viet nam.
Van-Hai PhamSchool of Information and Communications Technology, Hanoi University of Science and Technology, Hanoi, Viet nam.
Van-Thanh LeGraduate University of Science and Technology, Vietnam Academy of Science and Technology, Hanoi, Viet nam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of therapeutic target genes constitutes a critical yet challenging aspect of cancer research, primarily due to the inherent complexities of biological systems and the heterogeneity of molecular data. This study introduces BioRank, an innovative gene prioritization methodology that extends the traditional PageRank algorithm by integrating biological insights through a custom-designed vector. This vector synthesizes differential gene expression, functional annotations (derived from GO, KEGG, and Reactome), and coexpression similarity to achieve a classification of enhanced biological significance. BioRank was validated using RNA sequencing data from The Cancer Genome Atlas (TCGA), alongside protein-protein interaction networks from HIPPIE across seven cancer datasets. Experimental results illustrate that BioRank effectively facilitates the identification and prioritization of therapeutic target genes. Comparative analysis with previous methodologies indicates that BioRank achieves superior predictive performance concerning both the number of target genes in OncoKB, as well as Recall@ and nDCG@ metrics. BioRank operates as a research instrument designed for hypothesis generation, prioritizing candidate therapeutic target genes based on a specified cancer type and standard molecular/network inputs. This empowers researchers to prioritize genes for subsequent biological validation, such as functional assays, while simultaneously retrieving known targets and identifying under-explored candidates.

Indexed as

Biomolecular networksBioRankCancerDrug target geneGene expression information

Identifiers

PMID41142752
PMCPMC12546976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.